Virbac
2018 first quarter revenue rose by +3.3% at comparable exchange rates - Seite 2
Outside of the United States, the Group is growing at +0.2% at current rates, or +6.0% at constant rates. In Europe, revenue is growing at +4.9% at current rates (+5.5% at constant rates). The
principle contributors to this performance are France, Germany, Benelux, Poland, and the United Kingdom, which are all seeing a resurgence in activity in ranges for companion animals and are once
again benefiting from the availability of dog vaccines.
In Latin America, the Group had a good start to the year. Activity grew by +1.0% at current rates (+13.8% at constant exchange rates), thanks in particular to contributions by Mexico and
Brazil.
In Asia-Pacific, growth at current rates is at -3.6%; however, steady growth was once again maintained after adjusting for the impact of exchange rates (+6.3%), particularly in India, which was
severely punished by demonetization in early 2017, New Zealand, Thailand, and Japan.
In Chile, first quarter activity is down by -15.6% at current rates (-5.3% at constant rates), due to an algae bloom episode affecting the farms, the anticipated reduction in antibiotic sales, as
well as weaker vaccine sales compared to the first quarter of 2017, when sales had rebounded.
In terms of species, companion animals segment is growing overall at +4.0% at constant exchange rates (+9.5% outside the USA), primarily driven by strong performance in
specialty ranges, particularly anesthetic/tranquilizer ranges, and reproduction with Suprelorin. Dental ranges, dog vaccines and petfood also contributed greatly to the quarter's growth.
The food producing animals segment is seeing growth of +3.2% at constant rates. This performance is primarily due to the bovine sector, which is seeing good growth in the nutritionals, vaccines and
antibiotic ranges, thus offsetting the drop in industrial (swine and poultry). Aquaculture is down by -4.3% overall at constant rates. This growth is mixed: on the one hand, it reflects
double-digit growth (+29%) in Asia and, on the other hand, a decline in Chile as explained above.
Outlook
The Group anticipates growth in revenue at constant rates that in 2018 should show a low single-digit increase compared to 2017, and a current operating profit before depreciation of assets arising from acquisitions ratio on revenue at constant exchange rates, with growth at around 0.5 points compared to 2017. Debt relief should be around €30 million for the year. Furthermore, the Group obtained a relaxation of its financial covenant (net debt/Ebitda) with its bankers for 2018. Thus, it should be at 5.0 at the end of June, 2018, and at 4.25 at the end of December, 2018. Meanwhile, Virbac exercised the option of extending by two years the maturity date of its RCF (Revolving credit facility) of €420 million with its pool of banks, thereby extending this term financing to 2022 (2020 prior to the extension).
Lesen Sie auch
A laboratory that has always been dedicated to animal health
Virbac offers veterinarians, farmers and pet owners in more than 100 countries a comprehensive and practical range of products and services. With these innovative solutions covering the majority of
animal species and diseases, Virbac contributes, day after day, to shape the future of animal health.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Virbac via Globenewswire